Document Detail

Recombinant activated factor VII in cardiac surgery: a systematic review.
MedLine Citation:
PMID:  17258029     Owner:  NLM     Status:  MEDLINE    
Postoperative hemorrhage is a common complication in cardiac surgery, and it is associated with a considerable increase in morbidity, mortality, and cost. Recombinant activated factor VII (rFVIIa) is an emerging hemostatic agent, increasingly used in cardiac surgery. This article systematically reviews the evidence regarding the efficacy, safety, and cost of rFVIIa in this setting. Although definitive evidence from randomized controlled trials is lacking, the use of rFVIIa in patients experiencing refractory postoperative hemorrhage seems promising and relatively safe. However further research is required to definitively establish its clinical utility in the postoperative cardiac patient.
Oliver Warren; Kaushik Mandal; Vassilis Hadjianastassiou; Lisa Knowlton; Sukhmeet Panesar; Kokotsakis John; Ara Darzi; Thanos Athanasiou
Related Documents :
15323579 - Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leuk...
17186199 - Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome wi...
11353959 - Advantages of laparoscopic resection for ileocolic crohn's disease. improved outcomes a...
17268039 - Bivalirudin versus heparin plus glycoprotein iib/iiia inhibitors in drug-eluting stent ...
10858839 - Economic aspects of different muscle relaxant regimens.
11932599 - Carpal tunnel release in the united states and sweden: reimbursement patterns, cost for...
22778159 - Adherence to recommendations for the use of antifungal agents in a tertiary care hospital.
21091899 - Transparent cap improves patients' tolerance of colonoscopy and shortens examination ti...
1550149 - Prostaglandin e2 for induction of labor in patients with premature rupture of membranes...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Annals of thoracic surgery     Volume:  83     ISSN:  1552-6259     ISO Abbreviation:  Ann. Thorac. Surg.     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-01-29     Completed Date:  2007-03-06     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  15030100R     Medline TA:  Ann Thorac Surg     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  707-14     Citation Subset:  AIM; IM    
Department of BioSurgery and Surgical Technology, Imperial College Faculty of Medicine, St. Mary's Hospital, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiac Surgical Procedures*
Drug Costs
Factor VII / adverse effects,  economics,  therapeutic use*
Factor VIIa
Hemorrhage / drug therapy,  prevention & control
Hemostasis, Surgical / methods*
Recombinant Proteins / adverse effects,  economics,  therapeutic use
Treatment Outcome
Reg. No./Substance:
0/Recombinant Proteins; 0/recombinant FVIIa; 9001-25-6/Factor VII; EC VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Transverse bronchoplasty of the membranous wall after resection of an endobronchial hamartoma.
Next Document:  Selecting a vasopressor drug for vasoplegic shock after adult cardiac surgery: a systematic literatu...